| Trial registration number
|
IRCT20211221053470N1 |
Full text link
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
http://en.irct.ir/trial/60815
|
First author
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
World Health Organization
|
Contact
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
erecruit@who.int
|
Registration date
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
2022-01-11
|
Recruitment status
Last imported at : Dec. 22, 2022, 12:23 p.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Completed
|
Study design
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
RCT
|
Allocation
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Randomized
|
Design
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Parallel
|
Masking
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Open label
|
Center
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
multi-center
|
Study aim
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Treatment
|
Inclusion criteria
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Hospitalized patients with laboratory-confirmed COVID-19
Adults (age ≥18 years(
Not expected to be transferred within 72 hours
|
Exclusion criteria
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
In the view of their doctors, no contraindication to use relevant drugs
No evidence of pregnancy or hepatic disease in imatinib group
No evidence of heart failure, TB or liver disease in Infliximab group
|
Number of arms
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
3
|
Funding
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
World Health Organization
|
Inclusion age min
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
18
|
Inclusion age max
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
100
|
Countries
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Iran
|
Type of patients
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Moderate/severe/critical disease at enrollment
|
Severity scale
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
5: Moderate/severe/critical disease at enrollment
|
Total sample size
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
1000
|
primary outcome
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
In-hospital death from any causes
|
Notes
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
|
Phase
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
Phase 3
|
Arms
Last imported at : Jan. 12, 2022, 10:30 a.m.
Source : Iranian Registry of Clinical Trials (IRCT)
|
[{"arm_notes": "", "treatment_id": 650, "treatment_name": "Infliximab", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 631, "treatment_name": "Imatinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|